A5110148071- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Oral health in cancer treatment
- Renal Transplantation Outcomes and Treatments
- Mesenchymal stem cell research
- Acute Lymphoblastic Leukemia research
- Oral Health Pathology and Treatment
- Antifungal resistance and susceptibility
- Chronic Myeloid Leukemia Treatments
- Oral and gingival health research
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Platelet Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Cytomegalovirus and herpesvirus research
- Chronic Lymphocytic Leukemia Research
- DNA Repair Mechanisms
- Organ Transplantation Techniques and Outcomes
- CAR-T cell therapy research
- Viral-associated cancers and disorders
University of California, Berkeley
2025
Hillel Yaffe Medical Center
2024
Assuta Medical Center
2018-2022
Hadassah Medical Center
2009-2018
Hebrew University of Jerusalem
1999-2013
Hadassah Academic College
2000-2012
New York Blood Center
2011
Leukemia Research Foundation
2011
Shalvata Mental Health Center
2001
Tel Aviv Sourasky Medical Center
2001
This is the first report of treatment cytomegalovirus infection with artesunate, for a stem cell transplant recipient newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate resulted in 1.7-2.1-log reduction viral load by day 7, half-life 0.9-1.9 days, indicating highly effective block replication.
Summary ImMucin, a 21‐mer cancer vaccine encoding the signal peptide domain of MUC 1 tumour‐associated antigen, possesses high density T‐ and B‐cell epitopes but preserves specificity. This phase I/ II study assessed safety, immunity clinical response to 6 or 12 bi‐weekly intradermal ImMucin vaccines, co‐administered with human granulocyte‐macrophage colony‐stimulating factor 15 1‐positive multiple myeloma ( MM ) patients, residual biochemically progressive disease following autologous stem...
Summary Belantamab mafodotin, an immuno‐conjugate targeting B‐cell maturation antigen, showed single‐agent activity in phase 1 and 2 studies, was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real‐world data long‐term follow‐up are scarce. We conducted a multisite retrospective study aimed to assess safety efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One‐hundred six RRMM...
ABSTRACT The composition of the gut microbiome is determined by a complex interplay diet, host genetics, microbe-microbe interactions, abiotic factors, and stochasticity. Previous studies have demonstrated importance genetics in community assembly Caenorhabditis elegans identified central role for DBL-1/BMP immune signaling determining abundance Enterobacteriaceae . However, effects DBL-1 on bacteria were found to depend its activation extra-intestinal tissues, highlighting gap our...
Summary We reviewed our experience in the treatment of 13 patients with severe acquired aplastic anaemia, using a newly developed non‐myeloablative regimen consisting fludarabine (total dose 180 mg/m 2 ), cyclophosphamide 120 mg/kg), and antithymocyte globulin 40 mg/kg). All except one patient received multiple transfusions had failed prior immunosuppressive treatment. Twelve out achieved sustained engraftment. One was not evaluable for engraftment because early death on day +10. None graft...
In the mid-1990s, we introduced a fludarabine (Flu)-based conditioning regimen for hematopoietic stem cell transplantation (HSCT) in patients with Fanconi anemia (FA).The aim of this study is to compare Flu-based alternative regimens FA. Forty-one FA (aged 0.5-31, median, 10.3 years) who underwent allogeneic HSCT were included retrospective study. Hospital records reviewed regimens, engraftment data, and toxicity. The median (range) follow-up was 32 (0.5-149) months. used 24 patients: 17...
Reduced intensity conditioning has been suggested as a desirable therapeutic modality for the treatment of patients with malignant and nonmalignant indications, but it seems particularly attractive Fanconi anemia due to their increased sensitivity chemoradiotherapy. Between November 1996 September 2003, 7 (1 male 6 female; age range, 3-31 years; median age, 9.5) were conditioned fludarabine-based protocol stem cell transplantation without radiation. In vivo T-cell depletion was accomplished...
Chronic graft versus host disease (GvHD) is a major complication after allogeneic stem cell transplantation (SCT), which usually progression from acute GvHD. GvHD the main cause of severe morbidity and mortality in long-term survivors SCT. The cysteinyl leukotrienes (cysLTs) eosinophils play an important role pathogenesis GvHD, rationale for combined use montelukast (Mk) treatment this illness.Mk was administrated to 19 eligible patients with refractory chronic addition their standard...
The aim of this study was to validate the 2005-2006 National Institutes Health (NIH) scale for patient's self-reporting and clinical manifestations oral chronic graft-versus-host disease (cGVHD). Numerical parameters NIH were analyzed their construct validity (correlation with numerical rating [NRS] pain) internal consistency reliability between different same scale). Categoric by comparison severity subgroups defined manifestation (lichenoid/erythema/ulceration). Analysis included data 75...
Abstract To establish the safety of using G‐CSF in healthy PBSC donors, we prospectively determined degree DNA destabilization peripheral blood WBC. Donors were treated with SC for 5 days. A baseline sample was collected before treatment and consecutive samples on day 5, 1 month, 2 months after treatment. The extent double‐stranded relaxation de novo synthesis each sample. We found that both parameters significantly increased days returned to level at months. assume these findings suggest...